Purple Biotech Ltd (PPBT)

Oncternal Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cost of Revenue	0.06	0.06	0.2	0.12	0.06	0.06
Gross Profit	-0.06	-0.06	-0.2	-0.12	-0.06	-0.06
Selling, General & Admin	2.61	3.12	5.04	6.16	6.04	5.9
Research & Development	3.12	7.62	17.03	16.32	11.83	7.24
Operating Expenses	5.73	10.74	22.08	22.48	17.87	13.14
Operating Income	-5.79	-10.8	-22.27	-22.6	-17.92	-13.2
Interest & Investment Income	0.29	0.26	0.47	0.53	0.32	0.25
Currency Exchange Gain (Loss)	-0.01	-0.01	-0.01	0.06	-0.13	-0.01
Other Non Operating Income (Expenses)	2.89	3.48	1.83	0.25	-0.08	-15.71
EBT Excluding Unusual Items	-2.63	-7.08	-19.98	-21.76	-17.81	-28.66
Asset Writedown	-	-0.2	-	-	-	-
Legal Settlements	-	-	-	-	-0.01	-0.04
Pretax Income	-2.63	-7.28	-19.98	-21.76	-17.83	-28.7
Earnings From Continuing Operations	-2.63	-7.28	-19.98	-21.76	-17.83	-28.7
Earnings From Discontinued Operations	-	-	-	-	-0.64	0.63
Net Income to Company	-2.63	-7.28	-19.98	-21.76	-18.47	-28.07
Minority Interest in Earnings	0.02	0.04	0.1	0.09	0.08	0.08
Net Income	-2.61	-7.24	-19.88	-21.67	-18.38	-28
Net Income to Common	-2.61	-7.24	-19.88	-21.67	-18.38	-28
Shares Outstanding (Basic)	463	328	221	181	176	115
Shares Outstanding (Diluted)	463	328	221	181	176	115
Shares Change (YoY)	82.76%	48.17%	22.41%	2.92%	52.76%	493.78%
EPS (Basic)	-0.01	-0.02	-0.09	-0.12	-0.10	-0.24
EPS (Diluted)	-0.01	-0.02	-0.09	-0.12	-0.10	-0.24
Free Cash Flow	-8.83	-14.37	-19.93	-16.76	-15.37	-12.25
Free Cash Flow Per Share	-0.02	-0.04	-0.09	-0.09	-0.09	-0.11
EBITDA	-5.76	-10.77	-22.23	-22.4	-17.69	-12.96
D&A For EBITDA	0.03	0.03	0.05	0.2	0.23	0.24
EBIT	-5.79	-10.8	-22.27	-22.6	-17.92	-13.2

Updated May 21, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q